I. Craig Henderson, MD

Grinnell College, Grinnell, IA, A.B., 1963
Columbia University, College of Physicians & Surgeons, New York, NY, M.D., 1970

• 1970-1972
  Intern and Resident in Medicine, Presbyterian Hospital, New York, NY
• 1972-1974
  Research Associate, Viral Leukemia and Lymphoma Branch, NCI, Bethesda
• 1974-1975
  Clinical Fellow in Medicine, Sydney Farber Cancer Inst., Harvard Medical School (HMS)
• 1975-1976
  Instructor of Medicine, Sydney Farber Cancer Inst., HMS
• 1976-1984
  Assistant Professor of Medicine, Dana-Farber Cancer Inst., HMS
• 1979-1992
  Founder and Director, Breast Evaluation Center, Dana-Farber Cancer Inst., Boston
• 1981-1982
  Consultant, Cancer Unit, World Health Organization, Geneva, Switzerland
• 1982-1996
  Breast Core Committee, Cancer and Acute Leukemia Group B (Chairman 1990-1995)
• 1983-1993
  Subcommittee on Antineoplastic and Immunosuppressive Drugs, Committee on Essential Drugs, World Health Organization (Chairman 1983)
• 1984-1992
  Associate Professor of Medicine, Dana-Farber Cancer Inst., HMS, Boston
• 1985-1993
  World Health Organization Expert Advisory Panel on Cancer, Geneva
• 1985-1995
  Early Breast Cancer Trialists Collaborative Group (Oxford Overview Group) (Chairman 1985-1995)
• 1987-1990
  United States Congressional Office of Technology Assessment: Working Group on Immuno-Augmentative Therapy
• 1988-1994
  National Task Force on Breast Cancer Control, American Cancer Society
• 1989-1992
  Member, Oncologic Drugs Advisory Committee, FDA (Chairman 1990-1992)
• 1991-1993
  Education Committee, American Society of Clinical Oncology
• 1992-1995
  Professor of Medicine, University of California San Francisco (UCSF)
• 1992-1995
  Chief, Division of Oncology, Moffitt-Long-Mt. Zion
• 1992-1995
  Assoc. Director for Clinical Oncology in Comprehensive Cancer Center, UCSF (Interim)
• 1992-1996
  Founder, PI, Bay Area Breast Cancer Translational Research Program (NIH Specialized Program of Research Excellence, SPORE)
• 1996-present
  Steering Committee Member, Bay Area Breast Cancer Translational Research Program (NIH Specialized Program of Research Excellence, SPORE)
• 1995-present
  Adjunct Professor of Medicine, University of California San Francisco
• 1995-1999
  CEO and Chairman, SEQUUS Pharmaceuticals, Menlo Park Ca.
• 1999-present
  Senior Consultant, Alza Corporation, Mountain View, Ca. (Director 1999-2001)
• 2000-present
  Institute of Medicine Committee on Technologies for the Early Detection of Breast Cancer (Vice Chairman)
• 2000-present
  Breast Cancer Research Council of the State of California
• 2001-present
  President and Director, Access Oncology, Inc., New York City, NY

• 1966
  Merck, Sharpe and Dohme International Fellow, Columbia University
• 1970
  Research Prize, Columbia University Medical Society
• 1988
  Fellow, American College of Physicians
• 1987
  Henrietta Banting Memorial Lecturer, Canada
• 1992
  General Motors Cancer Research Foundation Lecturer, The Royal Marsden
• 1992
  Bernard L. Schwartz Lecturer, Scripps Memorial Hospitals
• 1993
  British Oncological Association Lecturer, United Kingdom
• 1993
  Distinguished Alumnus Award, Grinnell College
• 1994
  Doctorate of Science, Grinnell College
• 1996
  Wendell Scott Lecture, American College of Radiology
• 1997
  Fellow, Royal College of Physicians (Edinburgh)
• 1999
  Outstanding Industry Leader in Medical Research, California Pacific Medical Center Research Institute
• 2000
  Millennium Award from Bristol-Myers Squibb Oncology and Susan G. Komen Breast Cancer Foundation

• (selected from 232)
• Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton, L., Henderson, I.C.: Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001; 7:2703-11.
• Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton, L.: HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18:3471-9
• Cangialose CB, Blair AE, Borchardt JS, Ades TB, Bennett CL, Dickersin K, Gesme DH, Jr., Henderson IC, McGinnis LS, Jr., Mooney K, et al. Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services. Cancer 2000; 88:2876-86.
• Colbern GT, Hiller AJ, Musterer RS, Working PK, Henderson IC: Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer mode. J Inorg Biochem 77:117-20, 1999.
• Henderson IC: Chemotherapy of cancer, in Morris PJ, Wood WC (eds): Oxford Textbook of Surgery (ed 2nd). New York, Oxford University Press, 2000, pp 3435 3462
• Costanza ME, Weiss RB, Henderson IC, et al. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. Journal of Clinical Oncology 1999; 17:1397-406.
• Shapiro, C.L., Hardenbergh, P.H., Gelman, R., Blanks, D., Hauptman, P., Recht, A., Hayes, D.F., Harris, J., and Henderson, I.C.: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 11:3493-501, Nov 16, 1998.
• Henderson, I.C. Encapsulation of Nucleic Acids in Stealth Liposomes: Prospects for Enhanced Delivery to Occult Tumors After Intravenous Administration. In: Gene Therapy & Molecular Biology from Basic Mechanisms to Clinical Applications. Gene Therapy Press, Vol. 2, pp. 295-7 (1998).
• Budman, D.R., Berry, D.A., Cirrincione, C.T., Henderson, I.C., Wood, W.C., Weiss, R.B., Ferree, C.R., Muss, H.B., Green, M.R., Norton, L., and Frei III, E.: Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer. J. Natl. Cancer Inst. 90(16):1205-1211 (1998).
• Henderson, I.C. and Patek, A.J.: The Relationship Between Prognostic and Predictive Factors in the Management of Breast Cancer. Breast Cancer Research & Treatment 52:261-288, 1998.
• Henderson, I. C. "Breast Disorders". In: The Merck Manual for the General Public, R. Berkow, ed. Merck Sharp & Dohme Research Laboratories, West Point, Edition 1, In Press (1998).
• Berry, D. A., Thor, A., Cirrincione, C., Edgerton, S., Muss, H., Marks, J., Liu, E., Wood, W., Budman, D., Perloff, M., Peters, W., Henderson, I. C. "Scientific Inference and Predictions; Multiplicities and Convincing Stories: A Case Study in Breast Cancer Therapy" In: Bayesian Statistics 5: Proceedings of the 5th Valencia International Meeting, June 5-9, 1994, ed. Bernardo, J. M., Berger, J. O., Dawid, A. P., Lindley, D. V., Smith, A. F. M., Oxford University Press, Oxford, England, In Press (1996).
• Recht, A., Come, S. E., Henderson, I. C., Gelman, R. S., Silver, B., Hayes, D. F., Shulman, L. N., Harris, J. R.: "Five-Year Results of a Randomized Trial Testing the Sequencing of Chemotherapy and Radiation Therapy Following Conservative Surgery for Patients with Early-Stage Breast Cancer" N Engl J Med 334(21):1356-61 (1996).
• Ernster, V. L., Barclay, J., Kerlikowske, K., Grady, D., Henderson, I. C. "Incidence of and Treatment for Ductal Carcinoma in situ of the Breast." JAMA 275(12):913-8 (1996).
• Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., Norton, L. "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER-2/neu-Overexpressing Metastatic Breast Cancer" J Clin Oncol, 14(3):737-744 (1996)
• Muss, H. B., Thor, A., Berry, D. A., Kute, T., Liu, E.T., Koerner, F., Cirrincione, C.T., Budman, D.R., Wood, W. C., Barcos, M., Henderson, I. C., "c-erbB-2 Expression and S-Phase Activity, Predict Response To Adjuvant Therapy in Women with Node Positive Early Breast Cancer: A Comparison Study of the Cancer and Acute Leukemia Group B (CALGB)" New England Journal of Medicine, 330(18):1260-1266 (1994)
• Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., Ballow, A. C., Frei III, E., Henderson, I. C. "Dose and Dose Intensity Trial of Adjuvant Chemotherapy for Stage II, Node Positive Breast Carcinoma: Initial Results of CALGB 8541" New England Journal of Medicine, 330(18):1253-1259 (1994)
• Gray, J. W., Collins, C., Henderson, I. C., Isola, J., Kallioniemi, A., Kallioniemi, O. P., Nakamura, H., Pinkel, D., Stokke, T., Tanner, M., Waldman, F. "Molecular Cytogenetics of Human Breast Cancer" Cold Spring Harbor Symposia on Quantitative Biology, Cold Spring Harbor Laboratory Press, 59:645-52 (1994)
• Henderson, I. C. "Breast Cancer" In: Harrison's Principles of Internal Medicine, 13th Edition, K. J. Isselbacher, J. D. Wilson, E. Braunwald, J. B. Martin, A. S. Fauci, and D. L. Kasper, eds. McGraw-Hill, New York, pp. 1840-1850 (1994)
• Harris, J. R., Hellman, S., Henderson, I. C., and Kinne, D. W. (eds.). Breast Diseases, Second Edition, J.B. Lippincott, Co., Philadelphia, 1991.
• Gelman, R., Gelber, R., Henderson, I. C., Coleman, C. N., and Harris, J. R. Improved Methodology for Analyzing Local and Distant Failures. J. Clin. Oncol 3:548-555 (1990).
• Henderson, I. C., J. R. Harris, D. W. Kinne, and Hellman, S. "Breast Cancer". In: Cancer: Principles and Practice of Oncology, V. T. DeVita Jr., S. Hellman and S. A. Rosenberg, eds. J.B. Lippincott Company, Philadelphia, 1989, pp. 1197-1268.
• Henderson, I. C., Allegra, J. C., Woodcock, T., et. al. Randomized Clinical Trial Comparing Mitoxantrone with Doxorubicin in Previously Treated Patients with Metastatic Breast Cancer. J. Clin. Oncol. 7:560-571 (1989).
• Henderson, I. C., Hayes, D. F., and Gelman, R. Dose Response in the Treatment of Breast Cancer: A Critical Review. J. Clin. Oncol. 6:1501-1515 (1988).
• Early Breast Cancer Trialists Collaborative Group. The Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer: An Overview of 61 Randomised Trials Among 28,896 Women. New Engl. J. Med. 319:1681-1692 (1988).
• Tondini, C., Hayes, D. F., Gelman, R., Henderson, I. C., and Kufe, D. W. Comparison of CA15-3 and Carcinoembryonic Antigen in Monitoring the Clinical Course of Patients with Metastatic Breast Cancer. Cancer Res. 48:4107-4112 (1988).
• Henderson, I. C., and Canellos, G. P. Cancer of the Breast: The Past Decade. N. Engl. J. Med. 302:17-30, 78-90 (1980).
• Henderson, I. C., Lieber, M. M., and Todaro, G. J. Mink Cell Line MvlLu (CCL 64): Focus Formation and the Generation of Non-Producer Transformed Cell Lines with Murine and Feline Sarcoma Viruses. Virology 60:282-287 (1974).
• Henderson, I. C., and Livingston, D.M. Partial Purification and Characterization of the SV40 T-antigen. Cell 3:65-70 (1974).
• Henderson, I. C., and Loeb, J. N. Fall in Liver DNA Polymerase Activity in Cortisone-treated Rats. Nature 228:556-557 (1970).